SCHEMBL667300

SCHEMBL667300

COC(C)(C)OC(=O)C=CC#N

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3156742 0.83 HCAR2 (0.46) KEAP1NFE2L2HCAR2
SCHEMBL3156753 0.83 HCAR2 (0.46) KEAP1NFE2L2HCAR2
SCHEMBL10595070 0.83 HCAR2 (0.46) KEAP1NFE2L2HCAR2
SCHEMBL2569308 0.81 CTSK (0.34)
SCHEMBL4891444 0.79
SCHEMBL1068194 0.77 HCAR2 (0.35) KEAP1NFE2L2HCAR2
SCHEMBL1068196 0.77 HCAR2 (0.35) KEAP1NFE2L2HCAR2
SCHEMBL10596883 0.75 HCAR2 (0.54) KEAP1NFE2L2HCAR2
SCHEMBL10595074 0.75 HCAR2 (0.54) KEAP1NFE2L2HCAR2
SCHEMBL10595078 0.75 HCAR2 (0.54) KEAP1NFE2L2HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606719-B2 Methods and compositions comprising biodegradable cyanoacrylates FEMASYS INC. (US) 2026-04-21 US claimed
US-20260062590-A1 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FOR MEDICAL APPLICATIONS FEMASYS INC (US) 2026-03-05 US claimed
EP-4613213-A2 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FOR MEDICAL APPLICATIONS Femasys, Inc. (US) 2025-09-10 EP claimed
EP-3579890-B1 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FEMASYS INC (US) 2025-06-18 EP claimed
US-20230390105-A1 METHODS AND DEVICES FOR CONTROLLED DELIVERY POINTILLIST GLOBAL MACRO SERIES OF POINTILLIST PARTNERS LLC 2023-12-07 US claimed
EP-3787533-A1 METHODS AND DEVICES FOR CONTROLLED DELIVERY Femasys, Inc. (US) 2021-03-10 EP claimed
WO-2018148453-A1 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FEMASYS, INC. (US) 2018-08-16 WO claimed
EP-2618741-B1 APPLICATOR FOR DISPENSING ADHESIVE ADHEZION BIOMEDICAL LLC (US) 2018-04-04 EP claimed
EP-2211727-B1 CYANOACRYLATE TISSUE ADHESIVES ADHEZION BIOMEDICAL LLC (US) 2014-03-12 EP claimed
US-8550737-B2 Applicators for dispensing adhesive or sealant material ADHEZION BIOMEDICAL, LLC (US) 2013-10-08 US claimed
US-12606719-B2 Methods and compositions comprising biodegradable cyanoacrylates FEMASYS INC. (US) 2026-04-21 US disclosed
US-12582546-B2 Methods and devices for controlled delivery FEMASYS INC. (US) 2026-03-24 US disclosed
US-20260062590-A1 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FOR MEDICAL APPLICATIONS FEMASYS INC (US) 2026-03-05 US disclosed
EP-4613213-A2 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FOR MEDICAL APPLICATIONS Femasys, Inc. (US) 2025-09-10 EP disclosed
US-20250228644-A1 METHODS FOR MARKING A TARGET LOCATION FOR A MEDICAL PROCEDURE EPHEMERAL SOLUTIONS, INC. 2025-07-17 US disclosed
US-20090024155-A1 Methods and Devices for Conduit Occlusion FEMASYS, INC. 2009-01-22 US disclosed
US-20090024108-A1 Methods and Devices for Delivery of Compositions to Conduits FEMASYS, INC. 2009-01-22 US disclosed
US-20080293872-A1 ADHESIVES, SEALANTS AND COATINGS CONTAINING GLASS PARTICLES AS A FILLER HENKEL AG & CO. KGAA (DE) 2008-11-27 US disclosed
US-20080287574-A1 ADHESIVES, SEALANTS AND COATINGS CONTAINING GLASS PARTICLES AS A FILLER HENKEL AG & CO. KGAA (DE) 2008-11-20 US disclosed
WO-2008059541-A1 COSMETIC PRODUCT FOR THE TREATMENT OF CICATRICIAL TISSUES METIS S.R.L. (IT) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062590-A1 METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES FOR MEDICAL APPLICATIONS PGF, ACR, FGB KEAP1 3617/4885NFE2L2 3027/4885HCAR2 465/4885
US-12582546-B2 Methods and devices for controlled delivery PGF, GNRHR, LHCGR KEAP1 3961/4885NFE2L2 4602/4885HCAR2 2700/4885
US-12606719-B2 Methods and compositions comprising biodegradable cyanoacrylates MKI67, ACR, PGF KEAP1 3017/4885NFE2L2 2639/4885HCAR2 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.